Detailed Information on Publication Record
2016
The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature
SIMONSEN, Anja Hviid, Bea KUIPERIJ, Omar Mukhtar Ali EL-AGNAF, Sebastian ENGELBORGHS, Sanna-Kaisa HERUKKA et. al.Basic information
Original name
The utility of -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature
Authors
SIMONSEN, Anja Hviid (208 Denmark), Bea KUIPERIJ (528 Netherlands), Omar Mukhtar Ali EL-AGNAF (634 Qatar), Sebastian ENGELBORGHS (56 Belgium), Sanna-Kaisa HERUKKA (246 Finland), Lucilla PARNETTI (380 Italy), Irena REKTOROVÁ (203 Czech Republic, guarantor, belonging to the institution), Eugeen VANMECHELEN (56 Belgium), Elisabeth KAPAKI (300 Greece), Marcel VERBEEK (528 Netherlands) and Brit MOLLENHAUER (276 Germany)
Edition
BIOMARKERS IN MEDICINE, LONDON, FUTURE MEDICINE LTD, 2016, 1752-0363
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30000 3. Medical and Health Sciences
Country of publisher
United Kingdom of Great Britain and Northern Ireland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.020
RIV identification code
RIV/00216224:14740/16:00089458
Organization unit
Central European Institute of Technology
UT WoS
000367011600004
Keywords in English
alpha-synuclein; biomarker; CSF; diagnosis; ELISA; Parkinson's disease
Tags
Tags
International impact, Reviewed
Změněno: 4/8/2016 09:41, Mgr. Eva Špillingová
Abstract
V originále
The discovery of -synuclein (-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of -syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of -syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of -syn has yielded novel insights into the variety of -syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of -syn as biomarker. We also suggest future approaches to use of CSF -syn in neurodegenerative diseases.
Links
ED1.1.00/02.0068, research and development project |
|